Skip to main content

Advertisement

Fig. 4. | BMC Cancer

Fig. 4.

From: Potential mechanisms of resistance to venetoclax and strategies to circumvent it

Fig. 4.

Mutation in the BH3-binding domain of BCL-2 in SC-1 cells confer resistance to venetoclax. a Table showing region/domain mutations reside in the cell lines identified by sequencing. b X-ray crystal structure of BCL-2 with F104L mutation, which is predicted to lower affinity for venetoclax. c General domain structure of BCL2 showing the amino acids mutationally altered in DLBCL. A, Ala; F, Phe; I, Ile; L, Lys; T, Thr; V, Val

Back to article page